Targeted deep sequencing of solid tumors to predict response to therapy: A study in an Indian population.

e22059 Background: Massively parallel deep sequencing of genes involved in cancer can provide a comprehensive understanding of the processes that drive an individual's cancer and potentially provide personalized therapy options. Single gene sequencing based tests may provide an incomplete understanding of oncogenic pathways and response to therapy. We evaluated the utility of an NGS-multi-gene panel based approach in impacting treatment in a wide range of solid tumors from an Indian population of patients Methods: DNA from saliva and FFPE blocks of 30 tumor samples from varied tissue types (lung, colon, breast, ovary, glioblastoma, head and neck) was taken from consenting patients and subjected to deep sequencing using Illumina’s TSCAP 48 gene panel and the MiSeq technology. The average coverage across 220 hot spots was greater than 1000X in each sample. Data was processed using Avadis NGS™. Mutations identified in the tumor but not in the paired normal DNA were assessed for ‘actionability’ i.e. impact on...